Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Catalyst Pharmaceuticals (CPRX) over the last 4 years, with Q3 2025 value amounting to $9.3 million.

  • Catalyst Pharmaceuticals' Amortizatization of Intangibles fell 1.07% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 76.84%. This contributed to the annual value of $37.4 million for FY2024, which is 1477.66% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Amortizatization of Intangibles of $9.3 million as of Q3 2025, which was down 1.07% from $9.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $9.3 million in Q3 2024 and a low of $580000.0 during Q4 2022
  • For the 4-year period, Catalyst Pharmaceuticals' Amortizatization of Intangibles averaged around $8.2 million, with its median value being $9.3 million (2024).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 146189.66% in 2023, then fell by 1.07% in 2025.
  • Over the past 4 years, Catalyst Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $580000.0 in 2022, then skyrocketed by 1461.9% to $9.1 million in 2023, then rose by 3.15% to $9.3 million in 2024, then changed by 0.0% to $9.3 million in 2025.
  • Its Amortizatization of Intangibles was $9.3 million in Q3 2025, compared to $9.3 million in Q2 2025 and $9.3 million in Q1 2025.